



European Porcine Brucellosis Standard Serum (EUPBSS)

iELISA (pig iELISA)

validation Ring-Trial




EU Reference Laboratory for Brucellosis
ANSES – Maisons-Alfort, France





- Its origins...
 - Infected herd with Brucella suis biovar 2 isolation
 - 200 mL from 5 infected pigs (individually tested) pooled
 - Aliquoted; Freeze-dried (2012)
 - Homogeneity checked (2013)
 - 20 ≠ vials tested at two dilutions, in duplicates around the estimated cut-off (1/64 – 1/256)
 - Comparison of OD mean of each vial
 - CV between the vials 4.85% 5.37% < 10%





The candidate

Preliminary testing

			Day 1 (08/04	4/0213)			Da	ay 2 (09/04/02	13)			Da	y 3 (10/04/02	13)	
Sample	DO1	DO2	S/P	Résultat (seuil 0,25)	CV%	DO1	DO2	S/P	Résultat (seuil 0,25)	CV%	DO1	DO2	S/P	Résultat (seuil 0,25)	CV%
EUPigBSS_1/2	1.58	1.63	1.04	Р	2.37		•	•							
EUPigBSS_1/4	1.46	1.52	0.97	Р	2.71					Not to	ested				
EUPigBSS_1/8	1.34	1.33	0.87	Р	0.45										
EUPigBSS_1/16	1.12	1.21	0.76	Р	5.19	1.105	1.171	0.72	Р	4.09	1.125	1.100	0.72	Р	1.58
EUPigBSS_1/32	0.94	0.97	0.62	Р	2.33	1.019	0.995	0.64	Р	1.70	0.834	0.864	0.55	Р	2.46
EUPigBSS_1/64	0.59	0.63	0.40	Р	n/a	0.573	0.561	0.36	Р	n/a	0.573	0.573	0.37	Р	n/a
EUPigBSS_1/128	0.53	0.41	0.30	Р	n/a	0.314	0.351	0.21	N	n/a	0.350	0.381	0.24	N	n/a
EUPigBSS 1/256	0.28	0.25	0.17	N	n/a	0.194	0.202	0.13	N	n/a	0.194	0.190	0.12	N	n/a
EUPigBSS_1/512	0.17	0.14	0.10	N	n/a	0.121	0.140	0.08	N	n/a	0.126	0.130	0.08	N	n/a
ISaBsS_1/4	0.67	0.69	0.44	Р	n/a	0.668	0.669	0.42	Р	n/a	0.677	0.683	0.44	Р	n/a
ISaBsS_1/8	0.54	0.52	0.34	Р	n/a	0.601	0.626	0.39	P	n/a	0.564	oe ⁵⁸¹	0.37	Р	n/a
ISaBsS_1/16	0.40	0.39	0.25	Р	n/a	0.386	0.427	0.26	125	O n/a	- 6401°	160.387	0.26	Р	n/a
ISaBsS_1/32	0.27	0.25	0.17	N	n/a	0.241	0.266	0.16	1,100	_f nA"	0.266	0.270	0.17	N	n/a
ISaBsS_1/64	0.17	0.17	0.11	N	n/a	0.151	0.156	Mea.	Viilier	n/a	0.153	0.145	0.10	N	n/a
Pig_Neg	0.05	0.05	0.03	N	n/a	0.043	6445	0.03	Dilles	n/a	0.043	0.047	0.03	N	n/a
	i				DO	، ` `	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	VSI 2							
					7	JO	Day L stored	24 h at 5±3°C	(09/04/0213)			Day 2 stored	24 h at 5±3°C	(10/04/0213)	
Sample				N N P P N N N	tion k	etwe	DO2	S/P	Résultat (seuil 0,25)	CV%	DO1	DO2	S/P	Résultat (seuil 0,25)	CV%
EUPigBSS_1/16				1211S	χιιο.	1.239	1.31	0.81	Р	4.05	1.229	1.29	0.82	Р	3.51
EUPigBSS_1/32			N	0 40.		0.799	0.93	0.55	Р	10.75	0.904	0.85	0.57	Р	4.54
EUPigBSS 1/64			, ,			0.662	0.61	0.40	Р	n/a	0.646	0.63	0.41	Р	n/a
EUPigBSS_1/128						0.347	0.36	0.22	N	n/a	0.327	0.31	0.21	N	n/a
EUPigBSS 1/256						0.224	0.22	0.14	N	n/a	0.226	0.21	0.14	N	n/a
EUPigBSS_1/512						0.120	0.13	0.08	N	n/a	0.132	0.14	0.09	N	n/a
												Day 1 stored	48h at 5±3°C	(10/04/0213)	
Sample											DO1	DO2	S/P	Résultat (seuil 0,25)	CV%
EUPigBSS_1/16											1.186	1.15	0.76	P	2.25
EUPigBSS 1/32											0.953	1.00	0.64	Р	3.69
EUPigBSS 1/64											0.647	0.68	0.43	Р	n/a
EUPigBSS_1/128											0.380	0.35	0.24	N	n/a
EUPigBSS 1/256											0.176	0.18	0.12	N	n/a
EUPigBSS 1/512											0.133	0.14	0.09	N	n/a



- Set the conditions of standardisation the EUPBSS in iELISA (pig iELISA)
- Initially comparison with ISaBsS
 - recent changes, ISaBsS = no longer recognized, neither distributed
- participating laboratories → test ≠ dilutions of the EU candidate sera
- laboratories that still have a vial of ISaBsS performed the comparison
- Kits were provided / EURL :
 \(\backslash harmonization of test conditions





- •The laboratories were provided with:
 - √ 4 vials of EUPBSS freeze-dried (1 extra)
 - ✓1 iELISA kit Ingezim Brucella Porcino


•In addition:


- √ 10 mL of negative porcine serum (dilution)
- ✓ If another kit is used routinely to perform iELISA : parallel testing
- 3 consecutive days testing






Protocol







Intra-vials \rightarrow homogeneity (3 vials) Inter-days \rightarrow stability (3 days at 4°C)





Protocol

•Dilutions tested (vial resuspended in 1 mL of distilled water) in duplicates

Final	Volume of ser		Vol. of neg	Total prepared	Total required vol.	
dilution	Pre-dilution	Volume (μl)	serum (μl)	vol. (μl)	for 3-day testing (μΙ)	
1/16	no (neat)	10	150	160	30	Divert dilution very ined (social dilution ast
1/32	no (neat)	10	310	320	30	<u>Direct dilution</u> required (serial dilution not
1/64	no (neat)	10	630	640	30	allowed)
1/128	1/64*	20	20	40	30	
1/256	1/64*	15	45	60	30	Direct dilution of a pro-dilution allowed
1/512	1/64*	10	70	80	30	Direct dilution of a pre-dilution allowed
1/1024	1/64*	10	150	160	30	

Dilution of ISaBsS

Final dilution	Vol. Standar	d serum (μl)	Vol. of neg	Total	Total required	
Final dilution	Pre-dilution	Volume (μl)	serum (μl)	prepared vol. (μl)	vol. for 3 days- testing (μl) ⁽²⁾	
1/8	no (neat)	10	70	80	30	
1/16	no (neat)	10	150	160	30	<u>Direct dilution</u> required (serial dilution
1/304	1/16*	10	180	190	30	not allowed)
1/400	1/16*	10	240	250	30	

Following the supplier instructions





- Invitation sent during summer 2013, protocol presented during 2013 WS
 - 23 participating laboratories (20 NRLs + OIE network)
- Package sent early September 2013 → DDL: 31/10/13
 - No trouble during shipment
- Results sent back in due time
- 4 laboratories tested 2 kits in parralel
- 9 labs tested ISaBsS








Validation criteria

- ISaBsS results... but available for few laboratories, important variability in the results, reliability of the results?
- OD blank, C+; C-
- Indexes and interpretation checked
- CV% (OD₁;OD₂) < 20%
 - 18 results not included

			ISa	BsS	
		1/8	1/16	1/304	1/400
_	DAY1	1/0/7	3/0/5	8/0/0	8/0/0
Ingezim	DAY 2	0/0/8	3/0/5	8/0/0	8/0/0
=	DAY 3	1/0/7	4/0/4	8/0/0	8/0/0
	DAY1	0/0/1	0/0/1	1/0/0	1/0/0
Other	DAY 2	0/0/1	0/0/1	1/0/0	1/0/0
	DAY 3	0/0/1	0/0/1	1/0/0	1/0/0





EUBsSS validation *

Other

DAY 2

DAY 3

0/0/3

0/0/3

0/0/3

1/0/2

1/0/2

2/0/1

2/0/1

2/0/1

3/0/0

3/0/0

3/0/0

3/0/0

0/0/3

0/0/3

EUPBSS Set 1



Results

EUPBSS Set 2

EUPBSS Set 3

		1/16	1/32	1/64	1/128	1/256	1/512	1/1024	1/16	1/32	1/64	1/128	1/256	1/512	1/1024	1/16	1/32	1/64	1/128	1/256	1/512	1/1024
_	DAY 1	0/0/24	0/0/24	0/0/24	2/0/22	23/0/1	24/0/0	24/0/0	0/0/24	0/0/24	0/0/24	3/0/21	23/0/1	24/0/0	24/0/0	0/0/24	0/0/24	0/0/24	2/0/22	23/0/1	24/0/0	24/0/0
Ingezim	DAY 2	0/0/24	0/0/24	1/0/23	1/0/23	23/0/1	24/0/0	24/0/0	0/0/24	0/0/24	0/0/24	2/0/22	22/0/2	24/0/0	24/0/0	0/0/24	0/0/24	0/0/24	2/0/22	23/0/1	24/0/0	24/0/0
	DAY 3	0/0/24	0/0/24	0/0/24	3/0/21	24/0/0	24/0/0	24/0/0	0/0/24	0/0/24	0/0/24	3/0/21	23/0/1	24/0/0	24/0/0	0/0/24	0/0/24	0/0/24	5/0/19	23/0/1	24/0/0	24/0/0
	DAY 1	0/0/4	0/0/4	1/0/3	1/0/3	2/0/2	4/0/0	4/0/0	0/0/4	0/0/4	1/0/3	1/0/3	3/0/1	4/0/0	4/0/0	0/0/4	0/0/4	1/0/3	2/0/2	3/0/1	4/0/0	4/0/0
Other	DAY 2	0/0/3	0/0/3	1/0/2	1/0/2	2/0/1	3/0/0	3/0/0	0/0/3	0/0/3	1/0/2	1/0/2	2/0/1	3/0/0	3/0/0	0/0/3	0/0/3	1/0/2	1/0/2	2/0/1	3/0/0	3/0/0
	DAY 3	0/0/3	0/0/3	0/0/3	2/0/1	2/0/1	3/0/0	3/0/0	0/0/3	0/0/3	1/0/2	2/0/1	2/0/1	3/0/0	3/0/0	0/0/3	0/0/3	1/0/2	2/0/1	2/0/1	3/0/0	3/0/0
			•			_				•		•	'			_			•	•		
														1 h	ome	-mad	e kit					
																-mad ver O						
									CV>	>20% €	exclud	led (n	=18)									
				EU	JPBSS Set	t1			CV>	-20% €		l ed (n	·					EU	JPBSS Se	t 3		
		1/16	1/32	1/64	JPBSS Set	t1 1/256	1/512	1/1024	1/16 CA2	-20% €		·	·					1/64	J/128 Segal	1/256	1/512	1/1024
	DAY1	0/0/24			1/128	1/256	21/2/1		1/16	1/32	EL	J/128 Se	t 2 952/1	wit 1/512	1/1024	ver O	1/32	1/64		1/256		22/0/0
ngezim	DAY 1 DAY 2		0/0/24	1/64	2/0/22	22/0/1		23/0/0	0/0/24	0/0/24	0/0/23 1/64	PBSS Se 871/1 3/0/21	t 2 952/1 23/0/1	23/0/0 215/1 215/1	h low	91/1 0/0/24	0/0/24	0/0/24	2/0/22	23/0/1		22/0/0
Ingezim		0/0/24	0/0/24	0/0/24	2/0/22 1/0/23	22/0/1	24/0/0	23/0/0	0/0/24	0/0/24 0/0/24	0/0/23	3/0/21 2/0/22	23/0/1 22/0/1	215/1 23/0/0 24/0/0	24/0/0 23/0/0	0/0/24 0/0/24	0/0/24 0/0/24	0/0/24	2/0/22	23/0/1	24/0/0	22/0/0

7th Workshop of the EU Brucellosis NRLs - Berlin, Germany - September 8-9, 2014

0/0/3 1/0/2

1/0/2

1/0/2

2/0/1

1/0/1

2/0/1

3/0/0

2/0/0 3/0/0

3/0/0

0/0/3

0/0/3

0/0/3 1/0/2

0/0/3 1/0/2

1/0/2

2/0/1

1/0/1

2/0/1

2/0/0

3/0/0

3/0/0


2/0/0

0/0/3



Results

Index (mean) obtained by the participants for each dilution (whatever the testing-day, exc. CV> 20%)




- Positive results at 1/64
- Negative results at 1/512
- Consistent with EURL results



Results

Index (mean) obtained by the participants for each dilution & each testing day (exc. CV> 20%)



•No significative difference **between**

testing days

•No significative difference **between**

the vials



Proposed iELISA (pig iELISA) cut-off for EUPBSS

- Pos. At 1/64
- In between: P/N/D
 - Neg. at 1/512









European *Brucella ovis* Standard Serum (EUBoSS)

iELISA & CFT B. ovis

validation Ring-Trial




EU Reference Laboratory for Brucellosis ANSES – Maisons-Alfort, France







- Its origins...
 - Infected herd with Brucella ovis isolation
 - 1L from 3 infected sheep (individually tested) pooled
 - Aliquoted; freeze-dried (2012);
 - Homogeneity checked (2013)
 - 20 ≠ vials tested at two dilutions, in duplicates around the estimated cutoff (1/16 - 1/64)
 - Comparison of OD mean of each vial
 - CV between the vials 5.30% & 7.93%
 < 10%







The candidate

Preliminary testing

									ГІС	JIII I I	IIIai	y te	35UI	ig										
				Day 1 (08/	(04/0213)							Day 2 (09)								Day 3 (10)	 			
Sample	DO1	DO2	DO (%)	Résultat (seuil 30 % - 60 %)	Résultat (seuil 10 % - 50 %)	cv%	DO 30%	DO 60%	DO1	DO2	DO (%)	Résultat (seuil 30 %	Résultat (seuil 10 % -	CV%	DO 30%	DO 60%	DO1	DO2	DO (%)	Résultat (seuil 3 % - 60 %)	0 Résultat (seuil 10 % - 50 %)	CV%	DO 30%	DO 60%
ISaBoS 1/8	2.203	2.479	213.34	D /8 - 00 /8)	P	8.33	0.393	0.712	2.363	2.643	202.16	P	P	7.92	0.449	0.807	2.810	2.283	206.41	76 - 00 76)	P	14.64	0.442	0.800
ISaBoS 1/32	1.069		99.27	P	P	7,52		0.712	1.174	1.250	93.97	P	Р	4.46		0.807	1.287		93.04	P	P	11.03		0.800
ISaBoS_1/64	0.533	0.710	51.53	D	Р	20.13	0.393	0.712	0.662	0.747	51.44	D	Р	8.45	0.449	0.807	0.785	0.744	57.05	D	Р	3.76	0.442	0.800
ISaBoS_1/128	0.350	0.403	28.46	N	D	n/a	0.393	0.712	0.401	0.422	26.87	N	D	n/a	0.449	0.807	0.501	0.472	33.76	D	D	n/a	0.442	0.800
ISaBoS_1/256	0.215	0.237	14.30	N	D	n/a	0.393	0.712	0.217	0.237	11.42	N	D	n/a	0.449	0.807	0.286	0.264	16.02	N	D	n/a	0.442	0.800
ISaBoS_1/512	0.143	0.164	7.47	N	N	n/a	0.393	0.712	0.155	0.160	5.62	N	N	n/a	0.449	0.807	0.178	0.190	8.42	N	N	n/a	0.442	0.800
Ovin_Neg	0.078	0.084	0.68	N	N	n/a	0.393	0.712	0.100	0.102	0.85	N	N	n/a	0.449	0.807	0.109	0.325	11.18	N	D	n/a	0.442	0.800
																					//··			
Sample																			1	Day 3 (10, Résultat (seuil 3				1
																	DO1	DO2	DO (%)	% - 60 %)	10 % - 50 %)	CV%	DO 30%	DO 60%
ISaBoS -20°C_1/8																	2.642	2.539	210.10	Р	Р	2.80	0.442	0.800
ISaBoS -20°C_1/32																	1.257	1.317	100.86	Р	Р	3.29	0.442	0.800
ISaBoS -20°C_1/64																	0.765	0.807	58.89	D	Р	3.77	0.442	0.800
ISaBoS -20°C_1/128																	0.486	0.550	36.40	D	D	n/a	0.442	0.800
ISaBoS -20°C 1/256																	0.273	0.295	16.80	N	D	n/a	0.442	0.800
ISaBoS -20°C 1/512																	0.181	0.166	7.50	N	N	n/a	0.442	0.800
					/04/0213) Résultat (seuil 10 % - 50 %) P P P P D N N																			
				Day 1 (08/	(04/0213)							Day 2 (09)	(04/0213)		_			- 4	×0	Day 3 (10,	/04/0213)			
Sample	DO1	DO2	DO (0/)	Résultat (seuil	Résultat (seuil	01/0/	D.O. 000/	D 0 500/	DO1	DOS	DO (0/)	Résultat	Résultat		17	D.O. 500/	DO1 1	~kg	50000	Résultat (seuil 3	Résultat (seuil	01.00/	D.O. 000/	D.O. COO/
	DO1	DO2	DO (%)	30 % - 60 %)	10 % - 50 %)	CV%	DO 30%	DO 60%	DOT	DO2	DO (%)	(seuil 30 %	(seuil 10 % -	14TD	D0 20%	DO 60%	こっぱて	Our Service	DO (%)	% - 60 %)	10 % - 50 %)	CV%	DO 30%	DO 60%
EUBovisBSS_1/2	2.838	2.980	266.77	Р	Р	3.45	0.393	0.712				T	α .	110	2	V	7							
EUBovisBSS_1/4	2.197	2.513	214.65	Р	Р	9.49	0.393	0.712	2.643	2.800	220.47	ME	\mathcal{O} .	4.07	(44)	0.807	2.721	2.490	211.36	Р	Р	6.27	0.442	0.800
EUBovisBSS 1/8	1.306	1.689	133.92	Р	Р	18.10	0.393	0.712	1.867	2.041	(56.18	P		Lithin.	0.449	0.807	2.050	1,874	157.42	Р	Р	6.33	0.442	0.800
EUBovisBSS 1/16	0.991	1.162	94.33	P	Р	11.20	0.393	0.712	1.088	1.26	89 86	Р	Ct2	Diñ.	0.449	0.807	1.360	1,416	109.29	Р	Р	2.85	0.442	0.800
EUBovisBSS_1/32	0.557	0.791	56.42	D	Р	24.55	0.393	0.712	0.606	0.682	46.37	-10	210	8.36	0.449	0.807	1.038	0.849	72.07	Р	Р	14.18	0.442	0.800
EUBovisBSS_1/64	0.322	0.364	25.30	N	D	n/a	0.393	0.7(2)	O_{2}	0.433	27.49	ייבוע	D	n/a	0.449	0.807	0.530	0.436	33.47	D	D	n/a	0.442	0.800
EUBovisBSS_1/128	0.196	0.226	12.90	N	D	n/a	0.393	0.712	0.234	0.229	11.78	N	D	n/a	0.449	0.807	0.272	0.245	14.65	N	D	n/a	0.442	0.800
EUBovisBSS 1/256	0.148	0.172	8.07	N	N	n/a	0.393	0.712	0.159	MAG	5.71	N	N	n/a	0.449	0.807	0.197	0.163	8.04	N	N	n/a	0.442	0.800
EUBovisBSS 1/512	0.097	0.112	2.90	N	N	n/a	0.393	0.712	ner	0.133	3.12	N	N	n/a	0.449	0.807	0.134	0.125	3.83	N	N	n/a	0.442	0.800
							ati	ΩU																
						ar'	いるい	O 1			Day 1 s	tored 24 h at	5±3°C (09/04)	/0213)					Da	ay 2 stored 24 h at	5±3°C (10/04/02:	13)		
Sample				•	10 V	a			204	DOO	DO (0/)	Résultat	Résultat				D04	D00	DO (01)	Résultat (seuil 3	Résultat (seuil			
				,	1/10 .				DO1	DO2	DO (%)	(seuii 30 %	(seuii 10 % -	CV%	DO 30%	DO 60%	001	DO2	DO (%)	% - 60 %)	10 % - 50 %)	CV%	DO 30%	DO 60%
EUBovisBSS 1/4					•				2.532	2.631	208.74	D 70)	D P	2.73	0.449	0.807					1		+	
EUBovisBSS 1/8									1.829	1.982	152.08	P	P	5.67	0.449	0.807	1.917	1.800	148.72	Р	Р	4.45	0.442	0.800
EUBovisBSS 1/16									1.300	1.392	105.20	Р	Р	4.85	0.449	0.807	1.278		97.47	P	P	3.51	0.442	0.800
EUBovisBSS_1/32									0.798	0.807	59.66	D	Р	0.78	0.449	0.807	0.815	0.748	58.47	D	Р	6.14	0.442	0.800
EUBovisBSS_1/64									0.409	0.453	28.51	N	D	n/a	0.449	0.807	0.407	0.469	29.66	N	D	n/a	0.442	0.800
EUBovisBSS_1/128									0.221	0.270	12.99	N	D	n/a	0.449	0.807	0.248	0.240	13.40	N	D	n/a	0.442	0.800
EUBovisBSS_1/256									0.160	0.173	6.32	N	N	n/a	0.449	0.807	0.202	0.200	9.80	N	N	n/a	0.442	0.800
EUBovisBSS_1/512									0.130	0.135	3.48	N	N	n/a	0.449	0.807								
																			Da	ay 1 stored 48 h at	5±3°C (10/04/02	13)		
Sample																	DO1	DO2	DO (%)	Résultat (seuil 3		CV%	DO 30%	DO 60%
EUBovisBSS 1/4																			. ()	% - 60 %)	10 % - 50 %)		+	+
EUBovisBSS_1/4 EUBovisBSS 1/8																	1.883	1.793	147.03	P	P	3.46	0.442	0.800
EUBovisBSS 1/16																	1.883		94.50	P	P	1.51	0.442	0.800
EUBovisBSS 1/16																	0.826	0.711	57.42	D	P	10.56	0.442	0.800
EUBovisBSS_1/64																	0.826	0.711	28.54	N	D	n/a	0.442	0.800
EUBovisBSS_1/64 EUBovisBSS 1/128																	0.396	0.452	14.27	N	D	n/a n/a	0.442	0.800
EUBovisBSS 1/256																			7.09	N	N		0.442	0.800
EUBovisBSS 1/512																	0.165	0.172	7.09	N	IV	n/a	0.442	0.800
LUDUVISD33_1/31Z																			1		1	יכו ום	25 •	



- Set the conditions of standardisation the EUBoSS in iELISA (B. ovis iELISA)
- In comparison with ISaBoS (limited availability, one vial diluted 1/8)
- participating laboratories → test ≠ dilutions of the EU candidate sera in parallel with ISaBoSS
- Kits were provided / EURL : ↑ harmonization of test conditions





- •The laboratories were provided with:
- √ 4 vials of EUBoSS freeze-dried (1 extra)
- ✓ 1 vial of 500µl diluted ISaBoS (1/8)
- ✓ An iELISA kit Idexx Brucella ovis


•In addition:


- √ 10 mL of negative ovine serum (dilution)
- ✓ If another kit is used routinely to perform iELISA : parallel testing
- ✓ If B. ovis CFT is performed : parallel testing
- 3 consecutive days testing






Protocol







Intra-vials \rightarrow homogeneity (3 vials) Inter-days \rightarrow stability (3 days at 4°C)







•Dilutions tested (vial resuspended in 1 mL of distilled water) in duplicates

Final	Volume of ser		Vol. of neg	Total prepared	Total required vol.	
dilution	Pre-dilution	Volume (μl)	serum (μl)	vol. (μl)	for 3-day testing (μΙ)	
1/8	No (neat)	10	70	80	30	
1/16	No (neat)	10	150	160	30	<u>Direct dilution</u> required (serial dilution not
1/32	No (neat)	10	310	320	30	allowed)
1/64	No (neat)	10	630	640	30	
1/128	1/64*	20	20	40	30	
1/256	1/64*	15	45	60	30	Direct dilution of a pre-dilution allowed
1/512	1/64*	10	70	80	30	

Dilution to perform	Final dilution	Vol. of diluted (1/8) standard serum (μl)	Vol. of neg serum (μl)	Total prepared vol. (μl)	Total required vol. for 3 days- testing (µI) ⁽²⁾	
1/2	1/16	25	25	50	30	
1/4	1/32	15	45	60	30	<u>Direct dilution</u> required (serial
1/8	1/64	10	70	80	30	dilution not allowed)
1/64	1/512	10	630	640	30	

Following the supplier instructions







- Invitation sent during summer 2013, protocol presented during 2013 WS
 - 21 participating laboratories (19 NRLs + OIE network)
- Package sent early September 2013 → DDL: 31/10/13
 - No trouble during shipment
 - 1 lab had dilution troubles → parcel sent again
- Results sent back in due time
- 1 laboratories tested 2 kits in parralel
- 13 labs tested B. ovis CFT in parralel





Results

- Validation criteria
 - ISaBoS results (consistence between participants)
 - 3 labs were not included because of important Se discrepancies on ISaBosS & EUBoSS
 - OD blank, C+; C-
 - Indexes and interpretation checked
 - CV% (OD₁;OD₂) < 20%
 - 22 results not included
- Interpretation was conducted acc. to EURL's recommandations (Praud et al. 2012)

cut off: 30-60%

Praud et al. BMC Veterinary Research 2012, 8:68 http://www.biomedcentral.com/1746-6148/8/68



(Supplier 10-50%)

RESEARCH ARTICLE

Open Access


Assessment of the diagnostic sensitivity and specificity of an indirect ELISA kit for the diagnosis of *Brucella ovis* infection in rams

Anne Praud¹, Jean-Luc Champion², Yannick Corde³, Antoine Drapeau³, Laurence Meyer⁴ and Bruno Garin-Bastuji^{3*}





Results








Results

Index (mean) obtained by the participants for each dilution (whatever the testing-day, exc. CV> 20%)




- Positive results at 1/16
- •Negative results at 1/256
- Consistent with EURL results



Results

Index (mean) obtained by the participants for each dilution & each testing day (exc. CV> 20%)




- •No significative difference between **testing days**
- •No significative difference between vials






Results

CFT results (For information)





High titre ranges (>1 dilution): various protocol, antigens, ... lack of harmonization

Need of a validation trial with standardized protocol





Proposed iELISA cut-off for EUBoSS

- Pos. at 1/32
- In between: P/N/D
 - Neg. at 1/256

Proposed CFT validation trial for EUBoSS with standardized protocol





